Andere Sprachen Alterity Therapeutics Limited Nasdaq

Aktien

A3D4GD

US02155X2053

ATHE

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 24.05.2024			% 5 Tage	% 1. Jan.
2 ^USD	+3,11 %		0,00 %	-19,68 %

08.05.	Datenüberwachungskomitee der Phase 2 von Alterity Therapeutics empfiehlt nach dritter Überprüfung die Fortsetzung der klinischen Studie wie geplant	CI
29.04.	Alterity Therapeutics Limited stellt neue Daten vor, die das Potenzial von ATH434 zur Behandlung seltener neurodegenerativer Erkrankungen belegen	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review	08.05.
Alterity Therapeutics on Track to Complete Phase Two Trial of Lead Drug Candidate in November	08.05.
Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases	29.04.
ADRs End Lower, Purple Biotech Ltd. Declines 29%	16.04.
ADRs End Lower, Leju Holdings Ltd. Declines 72%	12.04.
ADRs End Higher, Lixiang Education Holding Co. Ltd. Climbs 69%	11.04.
ADRs Close Lower; VIA Optronics AG Declines 30%	10.04.
Top Midday Gainers	10.04.
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund	26.03.
Alterity Therapeutics Receives AU$3.9 Million R&D Tax Refund	26.03.
Alterity Therapeutics : Receives a $3.9 million Research & Development Tax Incentive Refund	26.03.
Genetic Technologies Appoints CFO	25.03.
Alterity Therapeutics : Voting ahead of attending the Meeting - Form 6-K	15.03.
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	29.02.
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 30, 2023	28.02.
Alterity Therapeutics Raises AU$3.3 Million for Clinical Trials; Shares Fall 20%	23.02.
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review	06.02.
Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review	06.02.
Alterity Therapeutics Advances Phase Two Multiple System Atrophy Trial Following Committee Recommendation	06.02.
Alterity Therapeutics Completes Securities Purchase Plan	02.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Alterity Therapeutics Limited Nasdaq

Aktien

A3D4GD

US02155X2053

ATHE

Andere Sprachen

Filter